PMID- 34444639
OWN - NLM
STAT- MEDLINE
DCOM- 20210831
LR  - 20210831
IS  - 1660-4601 (Electronic)
IS  - 1661-7827 (Print)
IS  - 1660-4601 (Linking)
VI  - 18
IP  - 16
DP  - 2021 Aug 23
TI  - Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use 
      Disorder Admissions in U.S. Substance Use Treatment Facilities.
LID - 10.3390/ijerph18168884 [doi]
LID - 8884
AB  - BACKGROUND: Naltrexone, a medication for addiction treatment (MAT), is an 
      FDA-approved medication recommended for the treatment of alcohol use disorder 
      (AUD). Despite the high prevalence of AUD and efficacy of naltrexone, only a 
      small percentage of individuals with AUD receive treatment. OBJECTIVES: To 
      identify trends for the prescription of naltrexone in AUD admissions in substance 
      use treatment centers across the U.S. METHODS: Data from the 2000-2018 U.S. 
      Treatment Episode Data Set: Admissions (TEDS-A) were used in temporal trend 
      analysis of naltrexone prescription in admissions that only used alcohol. Data 
      from the 2019 National Survey of Substance Abuse Treatment Services (N-SSATS) 
      were also used to characterize medication use among AUD clients across different 
      treatment service settings. RESULTS: Treatment of AUD with naltrexone was 0.49% 
      in 2000 and tripled from 0.53% in 2015 to 1.64% in 2018 in AUD admissions (p < 
      0.0001 for the Cochran-Armitage trend test). Women, middle-aged adults, and 
      admissions for clients living in the Northeast U.S. were more likely to be 
      prescribed naltrexone than their respective counterparts, as were admissions with 
      prior treatment episodes and referrals through alcohol/drug use care providers, 
      who paid for treatment primarily through private insurance, used alcohol daily in 
      the month prior to admission, and waited 1-7 days to enter treatment. Naltrexone 
      was more commonly prescribed by AUD admissions compared to acamprosate and 
      disulfiram and was more frequently prescribed in residential and outpatient 
      services as opposed to hospital inpatient services. CONCLUSIONS: Naltrexone 
      remains underutilized for AUD, and factors that influence prescription of 
      medication are multifaceted. This study may contribute to the creation of 
      effective interventions aimed at reducing naltrexone disparities for AUD.
FAU - Qeadan, Fares
AU  - Qeadan F
AUID- ORCID: 0000-0002-3376-220X
AD  - Department of Family and Preventive Medicine, University of Utah School of 
      Medicine, Salt Lake City, UT 84108, USA.
FAU - Mensah, Nana A
AU  - Mensah NA
AUID- ORCID: 0000-0002-8380-0390
AD  - Department of Family and Preventive Medicine, University of Utah School of 
      Medicine, Salt Lake City, UT 84108, USA.
FAU - Gu, Lily Y
AU  - Gu LY
AUID- ORCID: 0000-0003-2476-6257
AD  - Department of Family and Preventive Medicine, University of Utah School of 
      Medicine, Salt Lake City, UT 84108, USA.
FAU - Madden, Erin F
AU  - Madden EF
AD  - Department of Family Medicine and Public Health Sciences, Wayne State University, 
      Detroit, MI 48201, USA.
FAU - Venner, Kamilla L
AU  - Venner KL
AD  - Department of Psychology, Center on Alcohol, Substance Use, and Addiction 
      (CASAA), University of New Mexico, Albuquerque, NM 87131, USA.
FAU - English, Kevin
AU  - English K
AD  - Albuquerque Area Southwest Tribal Epidemiology Center, Albuquerque, NM 87110, 
      USA.
LA  - eng
PT  - Journal Article
DEP - 20210823
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
RN  - 0 (Alcohol Deterrents)
RN  - 5S6W795CQM (Naltrexone)
RN  - N4K14YGM3J (Acamprosate)
SB  - IM
MH  - Acamprosate/therapeutic use
MH  - Adult
MH  - *Alcohol Deterrents/therapeutic use
MH  - *Alcoholism/drug therapy/epidemiology
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Naltrexone/therapeutic use
MH  - *Substance-Related Disorders/drug therapy/epidemiology
PMC - PMC8394149
OTO - NOTNLM
OT  - TEDS-A
OT  - alcohol use disorder
OT  - medication for addiction treatment
OT  - naltrexone
COIS- The authors declare no conflict of interest.
EDAT- 2021/08/28 06:00
MHDA- 2021/09/01 06:00
PMCR- 2021/08/23
CRDT- 2021/08/27 01:21
PHST- 2021/07/28 00:00 [received]
PHST- 2021/08/19 00:00 [revised]
PHST- 2021/08/20 00:00 [accepted]
PHST- 2021/08/27 01:21 [entrez]
PHST- 2021/08/28 06:00 [pubmed]
PHST- 2021/09/01 06:00 [medline]
PHST- 2021/08/23 00:00 [pmc-release]
AID - ijerph18168884 [pii]
AID - ijerph-18-08884 [pii]
AID - 10.3390/ijerph18168884 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2021 Aug 23;18(16):8884. doi: 
      10.3390/ijerph18168884.